- Home
- IMCR vs VEON Comparison
IMCR vs VEON Comparison
Compare IMCR & VEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VEON
- Stock Information
- Founded
- IMCR 2008
- VEON 1992
- Country
- IMCR United Kingdom
- VEON United Arab Emirates
- Employees
- IMCR N/A
- VEON N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VEON Telecommunications Equipment
- Sector
- IMCR Health Care
- VEON Telecommunications
- Exchange
- IMCR Nasdaq
- VEON Nasdaq
- Market Cap
- IMCR 1.8B
- VEON 3.8B
- IPO Year
- IMCR 2021
- VEON 1996
- Fundamental
- Price
- IMCR $34.44
- VEON $52.61
- Analyst Decision
- IMCR Buy
- VEON Strong Buy
- Analyst Count
- IMCR 8
- VEON 1
- Target Price
- IMCR $57.00
- VEON $60.00
- AVG Volume (30 Days)
- IMCR 281.5K
- VEON 222.5K
- Earning Date
- IMCR 11-05-2025
- VEON 11-13-2025
- Dividend Yield
- IMCR N/A
- VEON N/A
- EPS Growth
- IMCR N/A
- VEON N/A
- EPS
- IMCR N/A
- VEON 13.63
- Revenue
- IMCR $356,145,000.00
- VEON $4,148,000,000.00
- Revenue This Year
- IMCR $31.83
- VEON $10.26
- Revenue Next Year
- IMCR $8.50
- VEON $7.02
- P/E Ratio
- IMCR N/A
- VEON $3.94
- Revenue Growth
- IMCR 26.78
- VEON 7.27
- 52 Week Low
- IMCR $23.15
- VEON $27.59
- 52 Week High
- IMCR $39.33
- VEON $64.00
- Technical
- Relative Strength Index (RSI)
- IMCR 50.52
- VEON 44.09
- Support Level
- IMCR $35.33
- VEON $50.00
- Resistance Level
- IMCR $36.76
- VEON $55.06
- Average True Range (ATR)
- IMCR 1.35
- VEON 2.80
- MACD
- IMCR 0.16
- VEON -0.77
- Stochastic Oscillator
- IMCR 40.16
- VEON 19.19
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VEON VEON Ltd. ADS
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.